- Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Will Adamed win against cancers? Part III of the interview with Dr Jerzy Pieczykolan about

Will Adamed win against cancers? Part III of the interview with Dr Jerzy Pieczykolan about 3-CLA project

Publish date: 2013-01-09

Adamed is a Polish pharmaceutical and biotech company focused on the next generation drug development and production. For over 25 years, the company has been providing pharmaceuticals to patients suffering from cardiology, pulmonology, gastroenterology, gynaecology, diseases of the central nervous system or ophthalmology. With robust R&D department, Adamed conducts researches on innovative oncology and neuropsychiatric therapies.

Tags: bioforum , biotechnology , poland , pharma

This project is an example of success story where there is no foreign capital, there was no acquisition of the project by huge pharma corporation or fusion with other companies, but successful collaboration with academia. How did you start the dialogue? How is it coordinated?

When the 3-CLA project began, we took a trip around Poland  to establish cooperation with as high as possible number of academic institution.  To the project realisation we started as a research team rich in the experience of former works carried out in Poland and abroad in the public and academic units. It seems to me that thanks to our experience we were able to establish the great way of settling the relation with academia. We believe that successful cooperation comes from the good agreement between scientists focused on particular research tasks. If there is a mutual understanding and will for co-operation , it can always be regulated also at the formal level.

How does the funding for the project work? The whole is estimated at 88 million PLN (€ 21 million).

More than half of the project is financed by Adamed and the remaining part by the funds of Polish National Centre for Research and Development. For this 88 million PLN (€ 21 million) consists ofinvestments of the both sides and VAT constituting for the costs not qualified for reimbursement from EU funds. Approximately half of the grant of 31 million PLN (€ 7.5 million) is devoted for the preclinical development in the strict sense meaning  production of the molecule of suitable  standards, realisation of toxicological studies and preparation of documentation enabling the start of clinical trials and execution of clinical phase I/II.  This means that for the entire research, which consists of design, production of proteins and their characterisation in vitro and in vivo, we had approximately 15 million PLN (€ 3.6 million) grant.

At what stage is the project now?

We can talk about two stages of molecule development, namely the non GLP pre-clinical stage, which has been finished for chosen particles. The project, however, still continues, because we were able to develop a number of very effective molecules, which despite extensive cooperation, were not fully tested to the desired extent. Thanks to the prolongation of the laboratory work by a year given by Polish National Centre for Research and Development, we have a chance to finish the research. We are sure that the work will result in submission of further patent applications to protect new, perhaps even more effective molecules.


What is included into the pre-clinical development in the GLP standard?

First of all, the production of those molecules in appropriate standard. Unfortunately, in Poland there is no institution able to produce this type of molecule of appropriate scale and standards. So we had to search abroad. Currently, we finish the talks about transfer of KNOW-HOW technologies to  our partners.  We pass the knowledge to the company, which will produce the molecules. At the same time, with several companies we develop the set of analytical procedures according to EMA and EMEA guidelines enabling so called release of these molecules. The difficulty lies in the fact that our fusion protein is new in its class – it is not an antibody or growth hormone. This molecule is completely unknown, therefore the development of suitable methodology, so as to meet the requirement of registration, is very  hard. The moment we finish the production process and development of analytical methods, we will get the first trials for toxicological studies.  It should take place in the first half of the 2013. As soon as we receive it, we will start the toxicological studies and, depending on whether we will be able to successfully pass the test panel, we will begin preparation of registration papers. Then, depending on the speed of the analysis of the documentation by the registration authority, we will be able to start the first phase of clinical trials.

Who will fund the clinical trials?

The grant we received will cover the costs of the first phase of clinical trials. However, it does not include the second and third phase of clinical trials and the costs here increase exponentially. Therefore, we see the opportunity for further development in cooperation with major pharma corporations who have the resources essential to complete the clinical development and introduction of the drug on the market.

Is it known who will be the licensee?

 List of potentially interested partners has already been defined. Our conversations have entered the confidential phase and therefore I cannot revealed details about their progress and who is involved in.

Genentech also tried  their hand at development of molecule of similar mode of action.

The molecule we are talking about is TRAIL protein (TNF-related apoptosis-inducing ligand). Genentech has been developing a recombinant variant of this molecule since 2000. It belongs to the components group of apoptotic cascade. The starting point for 3-CLA project was the assumption that TRAIL protein as individual apoptosis-inducing factor is not sufficient. Even then, there was a large number of publication claiming that cancers are resistant to TRAIL protein. In 2010, after many trials of the second clinical phase and lack of expected effectiveness Genentech company abandoned further development of TRAIL protein.

If, however, there were no research outcomes from Genentech company and numerous scientists  from which we also benefit, perhaps our project would not be at this stage of development as it is now.

You mentioned about the cooperation between Adamed, universities and foreign institution. How do you see the idea of BioForum fairs consolidating the biotech and biopharma sector in Central & Eastern Europe?

I believe that BioForum is a very valuable initiative. Adamed from the very beginning has participated in this event. For Polish companies alone, it s difficult to catch attention of large corporations and get them interested in researches carried out in our region. BioForum consolidates these activities and creates the critical mass essential for the existence on the international market of biopharmaceutical innovation.

Thank you for your time


Interview taken by Tomasz Sznerch

Translated by Jacek Plewka


Add comment
2016-04-03 06:23:28 +0200
My name is Jessica Luis, and I base in USA...My life is back!!! After 1 years of Broken marriage, my husband left me with two kids . I felt like my life was about to end i almost committed suicide, i was emotionally down for a very long time. Thanks to a spell caster called Dr Mohammed, which i met online. On one faithful day, as I was browsing through the internet,I came across allot of testimonies about this particular spell caster. Some people testified that he brought their Ex lover back, some testified that he restores womb,cure cancer,and other sickness, some testified that he can cast a spell to stop divorce and so on. i also come across one particular testimony,it was about a woman called Sonia,she testified about how he brought back her Ex lover in less than 2 days, and at the end of her testimony she dropped Dr Mohammed's e-mail address. After reading all these,I decided to give it a try. I contacted him via email and explained my problem to him. In just 48hours, my husband came back to me. We solved our issues, and we are even happier than before Dr Mohammed, is really a gifted man and i will not stop publishing him because he is a wonderful man... If you have a problem and you are looking for a real and genuine spell caster to solve all your problems for you. Try High anytime, he might be the answer to your problems. Here's his contact: or call him +2348134493948
2016-04-03 04:12:04 +0200
'After being in relationship with Wilson for seven years,he broke up with me, I did everything possible to bring him back but all was in vain, I wanted him back so much because of the love I have for him, I begged him with everything, I made promises but he refused. I explained my problem to someone online and she suggested that I should contact a spell caster that could help me cast a spell to bring him back but I am the type that don't believed in spell, I had no choice than to try it, I meant a spell caster called Dr Zuma zuk and I email him, and he told me there was no problem that everything will be okay before three days, that my ex will return to me before three days, he cast the spell and surprisingly in the second day, it was around 4pm. My ex called me, I was so surprised, I answered the call and all he said was that he was so sorry for everything that happened, that he wanted me to return to him, that he loves me so much. I was so happy and went to him, that was how we started living together happily again. Since then, I have made promise that anybody I know that have a relationship problem, I would be of help to such person by referring him or her to the only real and powerful spell caster who helped me with my own problem and who is different from all the fake ones out there. Anybody could need the help of the spell caster, his email: or call him +2349055637784 you can email him if you need his assistance in your relationship or anything. CONTACT HIM NOW FOR SOLUTION TO ALL YOUR PROBLEMS'
See also
For already 11 years, the BioForum trade fair ( has been attracting to Łódź, the centre of ... Read more
Tags: bioforum , czech republic
Central Europe (CE) is an emerging biotech market, a small star among European regions. There are more or less ... Read more
Tags: bioforum , biotechnology
HAYS Czech Republic, leading global experts in qualified in professional and skilled recruitment, joints to Bio... Read more
Tags: bioforum , czech republic